Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Expectorants, a subtype of mucoactive agents, are drugs used to facilitate the clearance of mucus from the airways by hydrating secretions and decreasing their viscosity. By increasing the volume and reducing the stickiness of bronchial mucus, expectorants such as guaifenesin help make coughs more productive and less frequent. Their mechanisms often include irritating gastric receptors to activate a reflex that increases respiratory tract secretion and modulating the secretion and properties of mucin glycoproteins in airway mucus. This target is a therapeutic mechanism, not a molecular target, and is thus not suitable to be treated as a receptor, enzyme, or similar entity.
Expectorants increase hydration/volume of mucus and decrease its adhesiveness and viscosity. They can stimulate vagal afferents in the gastric mucosa, increasing airway secretions by a gastro-pulmonary reflex, and modulate the secretion of mucin proteins (e.g., MUC5AC).
2 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Mucoactive agent (expectorant).